138 related articles for article (PubMed ID: 28600476)
1. Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.
Meulendijks D; Jacob W; Voest EE; Mau-Sorensen M; Martinez-Garcia M; Taus A; Fleitas T; Cervantes A; Lolkema MP; Langenberg MHG; De Jonge MJ; Sleijfer S; Han JY; Calles A; Felip E; Kim SW; Schellens JHM; Wilson S; Thomas M; Ceppi M; Meneses-Lorente G; James I; Vega-Harring S; Dua R; Nguyen M; Steiner L; Adessi C; Michielin F; Bossenmaier B; Weisser M; Lassen UN
Clin Cancer Res; 2017 Sep; 23(18):5406-5415. PubMed ID: 28600476
[No Abstract] [Full Text] [Related]
2. Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
Sequist LV; Gray JE; Harb WA; Lopez-Chavez A; Doebele RC; Modiano MR; Jackman DM; Baggstrom MQ; Atmaca A; Felip E; Provencio M; Cobo M; Adiwijaya B; Kuesters G; Kamoun WS; Andreas K; Pipas JM; Santillana S; Cho BC; Park K; Shepherd FA
Oncologist; 2019 Aug; 24(8):1095-1102. PubMed ID: 30975923
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.
Nishio M; Horiike A; Murakami H; Yamamoto N; Kaneda H; Nakagawa K; Horinouchi H; Nagashima M; Sekiguchi M; Tamura T
Lung Cancer; 2015 Jun; 88(3):275-81. PubMed ID: 25891541
[TBL] [Abstract][Full Text] [Related]
4. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
Schneeweiss A; Park-Simon TW; Albanell J; Lassen U; Cortés J; Dieras V; May M; Schindler C; Marmé F; Cejalvo JM; Martinez-Garcia M; Gonzalez I; Lopez-Martin J; Welt A; Levy C; Joly F; Michielin F; Jacob W; Adessi C; Moisan A; Meneses-Lorente G; Racek T; James I; Ceppi M; Hasmann M; Weisser M; Cervantes A
Invest New Drugs; 2018 Oct; 36(5):848-859. PubMed ID: 29349598
[TBL] [Abstract][Full Text] [Related]
5. Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.
Mendell J; Freeman DJ; Feng W; Hettmann T; Schneider M; Blum S; Ruhe J; Bange J; Nakamaru K; Chen S; Tsuchihashi Z; von Pawel J; Copigneaux C; Beckman RA
EBioMedicine; 2015 Mar; 2(3):264-71. PubMed ID: 26137564
[TBL] [Abstract][Full Text] [Related]
6. First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.
Meulendijks D; Jacob W; Martinez-Garcia M; Taus A; Lolkema MP; Voest EE; Langenberg MH; Fleitas Kanonnikoff T; Cervantes A; De Jonge MJ; Sleijfer S; Soerensen MM; Thomas M; Ceppi M; Meneses-Lorente G; James I; Adessi C; Michielin F; Abiraj K; Bossenmaier B; Schellens JH; Weisser M; Lassen UN
Clin Cancer Res; 2016 Feb; 22(4):877-85. PubMed ID: 26463709
[TBL] [Abstract][Full Text] [Related]
7. Accelerating drug development by efficiently using emerging PK/PD data from an adaptable entry-into-human trial: example of lumretuzumab.
Meneses-Lorente G; McIntyre C; Hsu JC; Thomas M; Jacob W; Adessi C; Weisser M
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1239-1247. PubMed ID: 28497320
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.
Shimizu T; Yonesaka K; Hayashi H; Iwasa T; Haratani K; Yamada H; Ohwada S; Kamiyama E; Nakagawa K
Cancer Chemother Pharmacol; 2017 Mar; 79(3):489-495. PubMed ID: 28144730
[TBL] [Abstract][Full Text] [Related]
9. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
Juric D; Dienstmann R; Cervantes A; Hidalgo M; Messersmith W; Blumenschein GR; Tabernero J; Roda D; Calles A; Jimeno A; Wang X; Bohórquez SS; Leddy C; Littman C; Kapp AV; Shames DS; Penuel E; Amler LC; Pirzkall A; Baselga J
Clin Cancer Res; 2015 Jun; 21(11):2462-70. PubMed ID: 26034219
[TBL] [Abstract][Full Text] [Related]
10. A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer.
Felip E; Ranson M; Cedrés S; Dean E; Brewster M; Martínez P; McNally V; Ross G; Galdermans D
Clin Lung Cancer; 2012 Nov; 13(6):432-41. PubMed ID: 22609229
[TBL] [Abstract][Full Text] [Related]
11.
Bensch F; Lamberts LE; Smeenk MM; Jorritsma-Smit A; Lub-de Hooge MN; Terwisscha van Scheltinga AGT; de Jong JR; Gietema JA; Schröder CP; Thomas M; Jacob W; Abiraj K; Adessi C; Meneses-Lorente G; James I; Weisser M; Brouwers AH; de Vries EGE
Clin Cancer Res; 2017 Oct; 23(20):6128-6137. PubMed ID: 28733442
[No Abstract] [Full Text] [Related]
12. Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies.
Guarino MJ; Schneider CJ; Hosford MA; Brahmer JR; Rudin CM; Finckenstein FG; Philip-Norton RE; Lu H; Weber MR; Ettinger DS
Oncologist; 2009 Feb; 14(2):119-24. PubMed ID: 19182243
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
Lin CC; Calvo E; Papadopoulos KP; Patnaik A; Sarantopoulos J; Mita AC; Preston GG; Mita MM; Rodon J; Mays T; Yeh IT; O'Rourke P; Takimoto CH; Dancey JE; Chen H; Tolcher AW
Cancer Chemother Pharmacol; 2009 May; 63(6):1065-71. PubMed ID: 18795291
[TBL] [Abstract][Full Text] [Related]
14. A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer.
Cejalvo JM; Jacob W; Fleitas Kanonnikoff T; Felip E; Navarro Mendivil A; Martinez Garcia M; Taus Garcia A; Leighl N; Lassen U; Mau-Soerensen M; Adessi C; Michielin F; James I; Ceppi M; Hasmann M; Weisser M; Cervantes A
ESMO Open; 2019; 4(4):e000532. PubMed ID: 31423336
[TBL] [Abstract][Full Text] [Related]
15. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
Weickhardt AJ; Price TJ; Chong G; Gebski V; Pavlakis N; Johns TG; Azad A; Skrinos E; Fluck K; Dobrovic A; Salemi R; Scott AM; Mariadason JM; Tebbutt NC
J Clin Oncol; 2012 May; 30(13):1505-12. PubMed ID: 22412142
[TBL] [Abstract][Full Text] [Related]
16. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
17. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells.
Kawakami H; Okamoto I; Yonesaka K; Okamoto K; Shibata K; Shinkai Y; Sakamoto H; Kitano M; Tamura T; Nishio K; Nakagawa K
Oncotarget; 2014 Dec; 5(23):11847-56. PubMed ID: 25474137
[TBL] [Abstract][Full Text] [Related]
18. Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer.
Yonesaka K; Hirotani K; von Pawel J; Dediu M; Chen S; Copigneaux C; Nakagawa K
Lung Cancer; 2017 Mar; 105():1-6. PubMed ID: 28236978
[TBL] [Abstract][Full Text] [Related]
19. A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer.
Rosen LS; Goldman JW; Algazi AP; Turner PK; Moser B; Hu T; Wang XA; Tuttle J; Wacheck V; Wooldridge JE; Banck M
Clin Cancer Res; 2017 Apr; 23(8):1910-1919. PubMed ID: 27803065
[No Abstract] [Full Text] [Related]
20. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Kirschbrown W; Holen KD; Rosen LS
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1025-32. PubMed ID: 26420235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
